Clinical Trial Update: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating HRO761 alone or in combination in cancer patients with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR), in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• HRO761

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers | Phase 1 | Status: ACTIVE_NOT_RECRUITING